News|Articles|March 31, 2026
Top FDA news in women's health you missed in Q1 2026
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Benjamin P. Saylor
Take a look back at some of the top FDA-related news items—from de Novo clearances to advancing trials—that Contemporary OB/GYN covered in the first quarter of 2026.
Advertisement
Advertisement
The first quarter of 2026 is all but in the books, with several noteworthy updates from the United States FDA having taken place. From federal agency feedback on testosterone therapy to updated labels for multiple menopausal hormone therapies, there was a lot to keep track of in women’s health in Q1.
Advertisement
Advertisement